| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
1-Naphthaleneboronic acid does not have a defined pharmacological target of its own, as it is a synthetic intermediate. As a boronic acid, it serves as a building block for Suzuki-Miyaura cross-coupling reactions. The naphthyl group is a common motif in various biologically active compounds and materials.
|
|---|---|
| ln Vitro |
In vitro, 1-naphthaleneboronic acid is primarily used as a chemical reagent and synthetic intermediate. It is a building block for Suzuki-Miyaura cross-coupling reactions to form carbon-carbon bonds. As a naphthyl boronic acid, it is a common reagent for the construction of biaryl compounds in medicinal chemistry, materials science, and organic synthesis.
|
| ln Vivo |
In vivo activity data for 1-naphthaleneboronic acid itself are not available, as the compound is not intended for direct in vivo administration. Rather, it is a precursor used in the synthesis of drug candidates that are subsequently evaluated in animal models.
|
| Enzyme Assay |
For in vitro chemical synthesis, 1-naphthaleneboronic acid is used as a reagent in Suzuki-Miyaura cross-coupling reactions. Standard protocols involve reacting the boronic acid with an aryl or alkyl halide in the presence of a palladium catalyst and a base in an appropriate solvent at elevated temperatures. The naphthyl group provides a rigid, aromatic scaffold that can influence the properties of derived compounds.
|
| Cell Assay |
For in vitro cell-based experiments, 1-naphthaleneboronic acid is used as an intermediate in the synthesis of compounds that are tested in cell viability, proliferation, and cytotoxicity assays. The compound itself is not typically evaluated in cell-based assays. Standard cell culture protocols for test compounds synthesized from this intermediate involve dissolving the final product in DMSO and diluting to working concentrations.
|
| Animal Protocol |
In vivo animal studies using 1-naphthaleneboronic acid are conducted on the final drug compounds synthesized from it, not on the intermediate itself. For pharmaceutical candidates derived from this building block, efficacy studies would typically be performed in mouse models of the relevant disease. Standard in vivo protocols involve administration to rodents via oral gavage or intraperitoneal injection.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 1-naphthaleneboronic acid as a standalone compound are not characterized in the literature. The compound has a molecular weight of 172.00 g/mol, which is within the favorable range for oral bioavailability. The naphthyl group may influence lipophilicity and metabolic stability.
|
| Toxicity/Toxicokinetics |
1-Naphthaleneboronic acid is a research chemical and should be handled with appropriate laboratory safety precautions. As a boronic acid derivative, it may cause skin and eye irritation. The compound is for research use only and not for human therapeutic or diagnostic applications. Specific LD₅₀ values and acute toxicity classifications are not available.
|
| Additional Infomation |
1-Naphthaleneboronic acid (1-Naphthylboronic acid, CAS 13922-41-3) is primarily a research-grade chemical intermediate, not an FDA-approved pharmaceutical drug. Its primary applications are as a building block for Suzuki-Miyaura cross-coupling reactions and as a sulfonylation reagent for organic synthesis and drug discovery. No clinical trials or approved therapeutic indications exist.
|
| Molecular Formula |
C10H9BO2
|
|---|---|
| Molecular Weight |
171.99
|
| Exact Mass |
172.069
|
| CAS # |
13922-41-3
|
| PubChem CID |
254532
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
381.9±25.0 °C at 760 mmHg
|
| Melting Point |
208-214 °C(lit.)
|
| Flash Point |
184.8±23.2 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.639
|
| LogP |
2.82
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
13
|
| Complexity |
172
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O([H])B(C1=C([H])C([H])=C([H])C2=C([H])C([H])=C([H])C([H])=C21)O[H]
|
| InChi Key |
HUMMCEUVDBVXTQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H9BO2/c12-11(13)10-7-3-5-8-4-1-2-6-9(8)10/h1-7,12-13H
|
| Chemical Name |
naphthalen-1-ylboronic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (581.43 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (14.54 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (14.54 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.8143 mL | 29.0715 mL | 58.1429 mL | |
| 5 mM | 1.1629 mL | 5.8143 mL | 11.6286 mL | |
| 10 mM | 0.5814 mL | 2.9071 mL | 5.8143 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
